Literature DB >> 1978227

Use of antiasthmatic drugs in Australia.

M A Jenkins1, S F Hurley, G Bowes, J J McNeil.   

Abstract

Bronchodilator prescription and sales data for Australia from 1975 to 1986 were analysed. Inhaled beta-agonists were the most commonly prescribed antiasthmatic agents in 1986, followed by sustained-release theophylline and inhaled corticosteroids. Marked increases in prescription sales of these three drug groups over the period were noted. We estimate that non-prescription sales of salbutamol inhalers increased by 410% between 1980 and 1986 (P less than 0.01). Prescribing rates by general practitioners for beta-agonists, sustained-release theophylline and inhaled corticosteroids increased from 1979 to 1986. Prescribing rates of beta-agonists were highest for persons aged 1-11 years and 55 years and over, and increased markedly for children aged 1-11 years over the period. For sustained-release theophylline, prescribing rates were highest for persons 55 years and over. The difficulties in postulating possible relationships between prescribing trends and asthma mortality are discussed.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1978227     DOI: 10.5694/j.1326-5377.1990.tb136939.x

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  7 in total

Review 1.  Pharmacoeconomic consequences of measurement and modification of hospital drug use.

Authors:  L L Ioannides-Demos; G M Eckert; A J McLean
Journal:  Pharmacoeconomics       Date:  1992-07       Impact factor: 4.981

2.  Asthma mortality in Australia 1920-94: age, period, and cohort effects.

Authors:  R Taylor; E Comino; A Bauman
Journal:  J Epidemiol Community Health       Date:  1997-08       Impact factor: 3.710

Review 3.  Clinical management of asthma in the 1990s. Current therapy and new directions.

Authors:  P Jain; J A Golish
Journal:  Drugs       Date:  1996       Impact factor: 9.546

Review 4.  The cost of asthma: can it be reduced?

Authors:  C M Mellis; J K Peat; A J Woolcock
Journal:  Pharmacoeconomics       Date:  1993-03       Impact factor: 4.981

Review 5.  Salmeterol. An appraisal of its quality-of-life benefits and potential pharmacoeconomic positioning in asthma.

Authors:  D H Peters; D Faulds
Journal:  Pharmacoeconomics       Date:  1995-06       Impact factor: 4.981

6.  Association between availability of non-prescription beta 2 agonist inhalers and undertreatment of asthma.

Authors:  P Gibson; D Henry; L Francis; D Cruickshank; F Dupen; N Higginbotham; R Henry; D Sutherland
Journal:  BMJ       Date:  1993-06-05

7.  A population-wide profile of prescription drug use in Saskatchewan, 1989.

Authors:  K Quinn; M J Baker; B Evans
Journal:  CMAJ       Date:  1992-06-15       Impact factor: 8.262

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.